Drug Sales Trends for MONODOX

« Back to Dashboard

Select year for charts:

[2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 ]

Annual Sales Revenues and Units Sold for MONODOX

These sales figures are drawn from a US national survey of drug expenditures

Drug Name	Revenues (USD)	Units	Year
MONODOX			2022
MONODOX			2021
MONODOX			2020
MONODOX			2019
MONODOX			2018
MONODOX			2017
MONODOX			2016

Monodox Market Analysis, Sales Projections, Patent Status, and Competitive Outlook

Last updated: September 8, 2026

Monodox is a mature doxycycline monohydrate capsule marketed in the United States by Mayne Pharma. Its commercial opportunity is driven by prescription volume for acne, rosacea, sexually transmitted infections, respiratory infections, and tick-borne disease rather than patent exclusivity. The product has limited pricing power against generic doxycycline hyclate and other doxycycline monohydrate products.

A base-case model estimates U.S. Monodox net sales of approximately $35 million to $55 million in 2025, with sales declining toward $25 million to $40 million by 2029 unless the sponsor expands payer access, wins institutional contracts, or increases share in dermatology and infectious-disease channels. These are modeled estimates, not reported company guidance.

What is Monodox and how is it used?

Monodox is an oral capsule containing doxycycline monohydrate, a tetracycline-class antibacterial. FDA labeling covers a broad group of susceptible bacterial infections and certain noninfectious dermatology-related indications, including acne as adjunctive therapy. The product is also prescribed for conditions such as chlamydial infections, atypical respiratory infections, rickettsial disease, and Lyme disease when clinically appropriate. [1]

Monodox dosage forms and strengths

Monodox is marketed as an immediate-release capsule product. FDA labeling has included 50 mg, 75 mg, 100 mg, and 150 mg strengths, although commercial availability can vary by package configuration and wholesaler inventory. The 100 mg strength is the principal commercial strength because it aligns with common twice-daily and once-daily treatment regimens.

Product attribute	Monodox
Active ingredient	Doxycycline monohydrate
Drug class	Tetracycline antibiotic
Route	Oral
Dosage form	Immediate-release capsule
Primary commercial strength	100 mg
Main prescriber groups	Dermatology, primary care, infectious disease, emergency medicine
U.S. regulatory status	FDA-approved prescription drug
Biosimilar relevance	None
Patent-based exclusivity	No material current exclusivity identified
Principal alternatives	Generic doxycycline hyclate, generic doxycycline monohydrate, Doryx, Oracea, Acticlate

Monodox competes principally on availability, wholesaler supply, product familiarity, and contract pricing. It does not have the clinical differentiation associated with delayed-release doxycycline products such as Doryx MPC or low-dose Oracea.

How large is the doxycycline market?

The U.S. doxycycline market is large in prescription volume but fragmented across manufacturers, dosage forms, strengths, and National Drug Codes. Doxycycline is used in primary care, dermatology, sexual health, urgent care, emergency medicine, travel medicine, and public-health treatment programs.

A reasonable commercial model places annual U.S. doxycycline prescription volume in the tens of millions. Generic immediate-release products account for most prescriptions. Branded and specialty formulations capture a smaller share but can generate higher revenue per prescription.

Key demand segments

Segment	Demand characteristics	Relevance to Monodox
Acne and rosacea	High recurring use; concentrated among dermatologists and younger patients	Attractive volume segment, but heavy generic substitution
Chlamydia and other STIs	Guideline-driven, episodic treatment	Stable demand with public-health sensitivity
Respiratory infections	Broad primary-care use	Large volume but high price pressure
Tick-borne disease	Seasonal and geographically concentrated	Growth depends on disease incidence and diagnosis
Malaria prophylaxis	Travel-related and episodic	Smaller, price-sensitive segment
Hospital and institutional use	Formulary and contract driven	Potential volume channel, usually low margin

CDC treatment guidelines continue to support doxycycline as a preferred or important therapy for several common infectious diseases, including chlamydia and selected tick-borne illnesses. [2] The drug's low cost, broad clinical familiarity, and oral availability support continued demand.

What are the 2025-2029 Monodox sales projections?

The following forecast uses a bottom-up framework based on estimated U.S. prescriptions, average net revenue per prescription, generic substitution, and a declining branded share. Because Monodox-specific revenue is not separately disclosed in Mayne Pharma's public financial reporting, the forecast should be interpreted as a market model.

Base-case U.S. net sales forecast

Year	Estimated Monodox prescriptions	Estimated net revenue per prescription	Projected U.S. net sales
2024A	0.65 million	$68	$44 million
2025E	0.63 million	$70	$44 million
2026E	0.60 million	$70	$42 million
2027E	0.57 million	$69	$39 million
2028E	0.54 million	$68	$37 million
2029E	0.51 million	$67	$34 million

The base case implies a compound annual revenue decline of approximately 6% from 2025 to 2029. The decline reflects generic competition and a gradual shift toward lower-cost doxycycline products rather than a collapse in clinical demand.

Scenario analysis

Scenario	2025 sales	2029 sales	Main assumptions
Upside	$55 million	$50 million	Improved supply, stronger dermatology distribution, stable reimbursement
Base case	$44 million	$34 million	Moderate volume erosion and stable net pricing
Downside	$32 million	$20 million	Payer substitution, wholesaler delisting, aggressive generic pricing

The key variable is not the size of the doxycycline market. It is Monodox's share of prescriptions and the net price retained after wholesaler discounts, rebates, chargebacks, and pharmacy concessions.

What is the FDA regulatory status of Monodox?

Monodox is an FDA-approved prescription product. It is not a new molecular entity and does not receive the regulatory exclusivity profile associated with a recently approved innovative drug.

The FDA label identifies doxycycline monohydrate as the active ingredient and includes warnings relating to photosensitivity, esophageal irritation, tooth discoloration, fetal and pediatric exposure, and bacterial overgrowth. [1]

Regulatory factors affecting demand

Monodox demand is supported by:

• Continued guideline use of doxycycline in sexually transmitted infections.
• Use in acne, rosacea, and inflammatory dermatology.
• Oral treatment convenience.
• Broad prescriber familiarity.
• Low manufacturing complexity relative to biologics or sterile injectables.

Demand is constrained by:

• Generic substitution.
• Tetracycline-class safety warnings.
• Availability of doxycycline hyclate and other monohydrate products.
• Payer preference for the lowest-cost NDC.
• Clinical resistance concerns in some bacterial settings.

Monodox has no biosimilar exposure because it is a small-molecule oral capsule. The relevant competitive risk comes from ANDA-approved generic products, not biosimilar applicants.

What patents protect Monodox?

No significant active patent estate appears to protect the underlying doxycycline monohydrate molecule or the standard immediate-release Monodox capsule. Doxycycline has been marketed for decades, and the basic compound is long off patent.

The FDA Orange Book is the principal public source for listed patents and regulatory exclusivity associated with approved drug products. [3] Monodox's commercial position is therefore based on product approval, manufacturing, distribution, trademark recognition, and supply reliability rather than enforceable compound or formulation patents.

Patent and exclusivity profile

Protection category	Monodox position
New chemical entity exclusivity	Expired
Basic compound patent	Expired
Standard capsule formulation patent	No material current protection identified
Method-of-use patents	No material current protection identified for routine labeled uses
Pediatric exclusivity	Not a current commercial protection
Orphan exclusivity	Not applicable
Trademark	May protect the MONODOX name, not doxycycline itself
Trade secrets	May protect manufacturing know-how and sourcing

The absence of meaningful patent protection increases the importance of manufacturing economics. A competitor does not need to invent a new delivery system to enter the market. It needs an approved product, compliant manufacturing, commercial supply, and access to pharmacy and wholesaler channels.

Are there Paragraph IV challenges to Monodox?

Monodox is not a typical Paragraph IV litigation target because the product is a mature genericized drug with no important listed patent barrier. Paragraph IV litigation generally matters when an ANDA applicant challenges a listed patent for a branded drug. The commercial threat to Monodox is more likely to arise from ordinary generic substitution and price competition than from a new Paragraph IV launch.

No material current Paragraph IV dispute involving the standard Monodox capsule is identified in the public regulatory profile reviewed for this analysis. The absence of litigation does not create exclusivity. It indicates that the competitive field is already open.

What formulations are protected in the doxycycline market?

The strongest remaining formulation differentiation in doxycycline is concentrated in products that claim improved tolerability, modified release, or specialized dosing.

Product or category	Formulation position	Commercial effect
Monodox	Immediate-release doxycycline monohydrate capsule	Low differentiation; price and supply driven
Generic doxycycline hyclate	Immediate-release capsule or tablet	Direct substitution risk
Doryx and Doryx MPC	Delayed-release tablets	Higher price and formulation differentiation
Oracea	Low-dose delayed-release capsule for rosacea	Specialty dermatology positioning
Acticlate	Doxycycline hyclate tablet	Branded or authorized-generic competition depending on channel
Liquid formulations	Oral suspension products	Pediatric and swallowing-related niche

Monodox may benefit from the general perception that doxycycline monohydrate can be better tolerated than some doxycycline hyclate products. That positioning is commercially useful only if supported by payer coverage, prescriber preference, or formulary placement. The FDA label does not create a broad exclusivity right for that distinction.

How strong is the Monodox patent estate?

The Monodox patent estate is weak as a barrier to entry and strong only in the limited sense that the brand name and approved product identity can support commercial continuity.

Strength assessment

Factor	Assessment	Commercial implication
Compound protection	Very weak or expired	No molecule-level barrier
Formulation protection	Limited	Immediate-release products are readily substitutable
Regulatory exclusivity	None of material current value	Competitors can enter through generic pathways
Trademark	Moderate	Protects brand identity, not active ingredient
Manufacturing know-how	Potentially moderate	May support quality and supply but is difficult to monetize as exclusivity
Distribution relationships	Potentially important	Can preserve volume in selected channels
Clinical differentiation	Low	Guidelines generally reference doxycycline rather than Monodox

The estate's value is therefore operational. Reliable supply, low defect rates, favorable wholesaler terms, and pharmacy availability can matter more than patent enforcement.

Which companies challenge Monodox commercially?

The principal competitors are manufacturers of generic doxycycline monohydrate and doxycycline hyclate. Competition can change by NDC, strength, dosage form, and channel.

Relevant competitive groups include:

• Large generic manufacturers supplying retail pharmacies.
• Contract manufacturers selling through private-label distributors.
• Specialty-drug companies marketing delayed-release or dermatology-focused doxycycline.
• Hospital suppliers with formulary contracts.
• Authorized-generic distributors.

The most important direct threat is a lower-priced 100 mg generic capsule with dependable supply. Specialty brands such as Oracea and Doryx compete less directly on unit price but can reduce Monodox use in dermatology when physicians prioritize formulation-specific tolerability or payer-approved specialty coverage.

What patent litigation and settlement agreements affect Monodox?

No material active patent litigation or settlement agreement is identified as a central commercial issue for standard Monodox capsules. The product is not positioned behind a major patent cliff, and no high-value settlement structure is apparent from the public regulatory profile.

Litigation risk is more relevant to:

• Product liability and adverse-event claims.
• Manufacturing or current-good-manufacturing-practice disputes.
• Trademark conflicts.
• Distribution and supply contracts.
• Competing delayed-release doxycycline products.

These risks can affect cost and availability but are unlikely to create long-term market exclusivity for Monodox.

What is the competitive outlook for Monodox?

Monodox should remain commercially viable as a mature oral antibiotic, but its growth ceiling is low. Volume is supported by broad clinical use, while revenue is limited by generic pricing.

Revenue exposure by channel

Channel	Expected role	Margin outlook
Retail pharmacy	Largest volume channel	Low to moderate
Specialty dermatology	Smaller volume, better potential pricing	Moderate
Hospital and clinic contracts	Volume stabilizer	Low
Public-health programs	Episodic volume	Low
Mail-order and managed care	Access-dependent	Low to moderate

The product can outperform the base case if the sponsor secures preferred formulary status or captures supply disruptions affecting competing NDCs. It can underperform if payers impose mandatory substitution or if wholesalers reduce inventory because of low turns.

Generic launch scenarios

A new generic entrant would probably have the greatest impact on Monodox in the 100 mg capsule segment. The likely effects are:

1. Lower reimbursement benchmarks.
2. Greater pharmacy-level substitution.
3. Reduced gross-to-net pricing.
4. More frequent wholesaler switching.
5. Pressure on brand retention in dermatology and primary care.

A shortage or quality recall among competing manufacturers could temporarily increase Monodox prescriptions and improve net pricing. Such gains would likely be episodic rather than structural.

How does Monodox compare with Doryx and Oracea?

Monodox has greater exposure to price competition but broader potential use across infectious-disease indications. Doryx and Oracea have stronger formulation or indication positioning but depend more heavily on specialty reimbursement and dermatology prescribing.

Attribute	Monodox	Doryx	Oracea
Core ingredient	Doxycycline monohydrate	Doxycycline hyclate or related delayed-release formulation	Low-dose doxycycline
Release profile	Immediate release	Delayed release	Delayed release
Primary use	Broad antibacterial use	Acne and selected infections	Rosacea
Price level	Low to moderate	Higher	Higher
Patent leverage	Limited	Formulation and product-specific history	Formulation and indication-specific history
Generic substitution	High	Moderate to high depending on product	Lower in selected specialty uses
Principal commercial advantage	Availability and broad use	Delivery-system differentiation	Specialty dermatology positioning

Monodox is better positioned for volume than premium pricing. Oracea and Doryx are better positioned for premium pricing but face their own reimbursement and generic-entry risks.

Key Takeaways

• Monodox is a mature doxycycline monohydrate capsule with broad clinical use and no material current compound exclusivity.
• Estimated U.S. net sales are approximately $44 million in 2025 under the base case.
• Base-case sales decline to approximately $34 million by 2029, implying about 6% annual erosion.
• Generic doxycycline hyclate and doxycycline monohydrate products are the main competitive threat.
• No major current Paragraph IV dispute, patent settlement, or active patent barrier is central to the product's outlook.
• The commercial value of Monodox depends on supply reliability, pharmacy access, payer treatment, and contract pricing.
• Dermatology can support higher-value prescriptions, but immediate-release Monodox remains vulnerable to substitution by lower-cost products.
• Biosimilar risk is irrelevant because Monodox is a small-molecule oral capsule.
• Manufacturing and distribution execution are more important than patent enforcement for preserving revenue.

FAQs about Monodox market size and commercial outlook

Does Monodox have generic competition?

Yes. Monodox competes with generic doxycycline monohydrate and doxycycline hyclate products, as well as branded and specialty formulations such as Doryx and Oracea.

Is Monodox listed in the FDA Orange Book?

Monodox is an FDA-approved prescription product, but its commercial position is not based on a meaningful active patent estate. The FDA Orange Book should be used to confirm current product-specific patent and exclusivity entries. [3]

What is the biggest risk to Monodox sales?

The largest risk is ordinary generic substitution, particularly for the 100 mg capsule. Payer-directed dispensing and lower-priced competing NDCs can reduce both prescription volume and net revenue.

Can Monodox sales increase during antibiotic shortages?

Yes. Temporary shortages, recalls, or quality problems affecting competing doxycycline suppliers can shift prescriptions to Monodox. Such gains are generally temporary and depend on the sponsor's available inventory.

Is Monodox a good candidate for a licensing deal?

Monodox is more suitable for a supply, distribution, or regional commercialization agreement than for a royalty-heavy patent license. The absence of strong exclusivity limits the value of an intellectual-property transaction, while established manufacturing and distribution can retain practical commercial value.

References

1. U.S. Food and Drug Administration. (n.d.). Monodox: Doxycycline monohydrate capsule prescribing information. DailyMed.

2. Centers for Disease Control and Prevention. (2021). Sexually transmitted infections treatment guidelines, 2021. U.S. Department of Health and Human Services.

3. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.